Affimed — Company Overview, News & Financial Data

Affimed NV (NASDAQ:AFMD) is a biopharmaceutical company deeply engaged in the development of immunotherapies to improve treatment outcomes for patients with cancer. Leveraging its proprietary ROCK® (Redirected Optimized Cell Killing) platform, Affimed NV designs and advances a pipeline of innate cell engagers that aim to harness the power of the body's own immune system. The company's lead projects focus on various hematologic and solid tumor indications, reflecting its commitment to bringing novel cancer treatments from concept through clinical trials to commercialization. With operations that span from early-stage research to advanced clinical trials, Affimed NV drives forward with the objective of transforming cancer treatment paradigms to offer hope and life-extending solutions to patients worldwide.